IJT

IJT remains in a bullish medium-term environment, supported by its overall uptrend and price above the 50-day and 200-day moving averages. Recent pullback into the short-term EMAs reflects consolidation after an advance, offering a potential entry zone near the sliding 9/20 EMA support. Overbought/oversold context is neutral, requiring a clear acceptance in the EMA region before committing. Medium-term structure remains constructive in Stage 2, favoring deferred bullish engagement at support. Key risk is a breakdown below the 9/20 EMA that could signal deeper correction toward the 50-day SMA.

• ↑Protagonist Therapeutics returned to profitability and raised FY guidance.
• ↑Fed pause prospects lower Treasury yields, easing small-cap borrowing costs.
• ↓IJT is exposed to volatile small-cap swings amid geopolitical tensions.